T1	HMM 841 872	pooled efficacy and safety data
T2	HMM 1022 1050	Median overall survival (OS)
T3	HMM 1319 1321	OS
T4	HMM 1443 1551	Ipilimumab-induced adverse events and immune-related adverse events (skin, gastrointestinal, hepatic, other)
